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Treatment of bacterial meningitis caused by Streptococcus
pneumoniae is increasingly difficult, because of emerging re-
sistance to antibiotics. Recombinant Cpl-1, a phage lysin spe-
cific for S. pneumoniae, was evaluated for antimicrobial ther-
apy in experimental pneumococcal meningitis using infant
Wistar rats. A single intracisternal injection (20 mg/kg) of
Cpl-1 resulted in a rapid (within 30min) decrease in pneumo-
cocci in cerebrospinal fluid (CSF) by 3 orders of magnitude
lasting for 2 h. Intraperitoneal administration of Cpl-1 (200
mg/kg) led to an antibacterial effect in CSF of 2 orders ofmag-
nitude for 3 h. Cpl-1may hold promise as an alternative treat-
ment option in pneumococcal meningitis.
Streptococcus pneumoniae causes severe infectious diseases, in-
cluding pneumonia, sinusitis, otitis media, bronchitis, septic ar-
thritis, endocarditis, and sepsis. It has also been shown to be the
leading cause of bacterial meningitis (47%), in a survey study
conducted in the United States [1]. Despite emerging vaccina-
tion strategies and the development of new antibiotics, pneumo-
coccal meningitis (PM) is still associated with a high mortality
rate, ranging from 19% to 26% [1]. Prompt and adequate anti-
microbial therapy reduces fatality rates to10% in infants and
children [2].
Antibiotic-resistant strains have emerged because of the ge-
netic plasticity of S. pneumoniae and the high exposure to anti-
biotic environments. Replacement by nonvaccine serotypes un-
der vaccination pressure has been demonstrated [3].
Phage lytic enzymes have recently been proposed for the re-
duction of nasopharyngeal carriage of S. pneumoniae [4 – 6].
Cpl-1, a lytic enzyme from the phage Cp-1 [7, 8], has been shown
to kill in vitro all tested serotypes of S. pneumoniae. By virtue of
its choline-binding domain, it displays an exquisite specificity
toward S. pneumoniae and can act synergistically with penicillin
and/or gentamicin in vitro [9]. Furthermore, Cpl-1 has success-
fully been tested as a therapy in rodent models of pneumococcal
sepsis [4, 6] and endocarditis [10]. It can also prevent otitis me-
dia caused by colonizing S. pneumoniae [11]. Here, we report on
the efficiency of Cpl-1 as an antimicrobial agent in an infant-rat
model of PM.
Methods. An established model of PM in infant rats was
used [12, 13]. The animal studies were approved by the Animal
Care and Experimentation Committee of Canton Bern, Switzer-
land, and National Institutes of Health guidelines for the perfor-
mance of animal experimentation were followed. Wistar rats
(Charles River Laboratories) were infected on postnatal day 11
by intracisternal (ic) injection of 10 L of a log10 5.7  0.3
cfu/mL suspension of a penicillin-susceptible clinical isolate of S.
pneumoniae (serogroup 3) [12, 13] in 0.85% NaCl saline solu-
tion.
To produce recombinant Cpl-1, this enzyme, a muramidase
of the S. pneumoniae–specific lytic phage Cp-1, was expressed in
Escherichia coli DH5(pJML6), purified to homogeneity using
DEAE column chromatography, and suspended in enzyme
buffer (50 mmol/L phosphate buffer [pH 7.0] with 1 mmol/L
EDTA and 1 mmol/L dithiothreitol). The specific activity, de-
fined elsewhere [5], of a freshly produced and purified batch was
1 U/g. Endotoxin was removed with ActiClean Etox (Stero-
gene Bioseparations).
The treatment regimen was as follows. Eighteen hours after
infection, cerebrospinal fluid (CSF) was harvested by ic punc-
ture and cultured quantitatively to document meningitis. Im-
mediately afterward, Cpl-1 was injected ic (600 U in 30 L [i.e.,
20 mg/kg of body weight] n  30) or intraperitoneally (ip; 6000
U in 300 L [i.e., 200 mg/kg of body weight]; n  24). Un-
treated infected animals (n  12) were injected ic with 30L of
sterile, pyrogen-free saline as control rats. Animals were killed at
30 min (n  8 for ic and n  4 for ip) , 1 h (n  7 for ic and
n  5 for ip), 2 h (n  4 for ic and n  5 for ip), 3 h (n  4 for
ic and n  5 for ip), and 4 h (n  7 for ic and n  5 for ip), and
samples of CSF and plasma were collected for determination of
bacterial titers by serial dilution and plating on sheep blood agar
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plates. Subsequently, the concentration of Cpl-1 was determined
in the samples after centrifugation at 4°C for 5 min at 10,000 g.
The volume of CSF that can be obtained from infant rats is sub-
ject to variation because of the individual clinical course of dis-
ease. Therefore, we were unable to both determine titers and
conduct Western blot analysis at all time points. When the
health status of an animal worsened rapidly because the biolog-
ical activity of Cpl-1 waned and the bacteria reestablished infec-
tion or because multiple ic injections caused clinical deteriora-
tion, it was euthanized for ethical reasons.
The lytic activity of Cpl-1 against the pneumococcal isolate
was tested in vitro by incubating 1  107 cfu of S. pneumoniae
with 30 U of Cpl-1 at room temperature in a total volume of 300
L. At 30 s and at 10 min after the start of the incubation, 10 L
was taken and immediately diluted 1:100 in ice-cold saline. Fur-
ther decimal dilutions were also performed with ice-cold saline.
The amount of Cpl-1 in CSF at different time points after
injection was assessed by Western blotting and spot densitome-
try. Briefly, proteins in 15 L of CSF or 1 L of plasma were
separated on a 12.5% SDS-polyacrylamide gel. Cpl-1 in serial
dilutions was added as standards. After transfer of the pro-
teins on a polyvinylidene fluoride membrane (Immobilon-P;
Pierce), Cpl-1 was detected as a 39-kDa band with a rabbit poly-
clonal antibody and an enhanced chemiluminescence detection
kit (Supersignal West Pico; Pierce). CSF or plasma from at least
2 animals was analyzed at each time point during the first 8 h
after Cpl-1 administration. A 1-phase exponential decay curve
was fitted to calculate the half-life, by means of GraphPad Prism
(version 4.03; GraphPad Software).
All statistical analyses were performed using GraphPad Prism.
For the difference in bacterial titers between different treatment
regimens, 2-way analysis of variance was performed. Compari-
son between groups was then performed with Bonferroni post-
tests. Because titers at 3 h were not determined for ic control rats,
this time point was excluded from the statistical analyses.
Results. The ability of Cpl-1 to kill the S. pneumoniae strain
used in this study was tested in vitro. Incubation of 1  107 cfu
of S. pneumoniae with 30 U of Cpl-1 for 30 s and 10 min, respec-
tively, decreased bacterial titers to below the detection limit
(1  103 cfu/mL) for both time points tested. This is in agree-
ment with the killing rate observed for other strains [6].
Cpl-1 was then evaluated as a candidate for the treatment of
experimental PM. After a single ic injection of 600 U (600g) of
Cpl-1, bacterial titers quickly decreased over the first 4 h,
whereas treatment with buffer had no effect (figure 1). Starting
at 30 min and for the next 2 h, CSF titers in rats treated with
Cpl-1 were at or below the detection limit. Soon after, pneumo-
cocci started to multiply again in CSF (figure 1). The amount of
Cpl-1 in each sample was calculated by densitometric scanning
of Western blots, using a standard curve of defined amounts of
Cpl-1 (figure 2). Cpl-1 was consistently detected in CSF during
the first 2 h after ic injection of 600 U in 2 independent experi-
ments, (figure 2C). The half-life of Cpl-1 in CSF was estimated to
be16 min (figure 2A). Thus, the regrowth of bacteria 4 h after
ic Cpl-1 administration was due to the short biological half-life
of Cpl-1 in CSF.
In a second approach that more closely modeled an envi-
sioned clinical application, Cpl-1 was administrated by ip injec-
tion (200 mg/kg of body weight). Western blot analysis of
plasma samples at different time points after infection demon-
strated that Cpl-1 was continuously released in the bloodstream
over the first 4 h after injection, and concentrations remained
stable between 50 and 60 g/mL (figure 2B and 2C). During the
same time, the corresponding bacterial titers in blood were be-
low the detection limit (1  103 cfu/mL). Importantly, a
marked reduction in bacterial titer in CSF was observed after ip
injection of Cpl-1 (figure 1, gray circles). After 2 h, titers de-
creased from a mean  SD of 6.99  0.11 to 5.23  0.6 log10
cfu/mL, representing a drop of 98%. This antibacterial effect was
detectable in CSF for as long as 4 h after initiation of ip therapy
Figure 1. Effect of intracisternal (ic) and intraperitoneal (ip) adminis-
tration of Cpl-1 on cerebrospinal fluid (CSF) bacterial titers. CSF bacterial
titers were unaffected by ic application of saline (white circles). Injection
of Cpl-1 ic (600 g; black circles) resulted in a rapid (within 30 min)
decrease in bacterial titer by 3 orders of magnitude. Injection of Cpl-1 ip
(6 mg; gray circles) led to the clearance of pneumococci from the CSF by
2 orders of magnitude until 3 h after administration. The limit of detection
for the determination of CSF bacterial titers was 1  104 cfu/mL of
undiluted CSF (dashed line). Two-way analysis of variance revealed that
both treatment and time after treatment were significant sources of
variation (P  .0001). Bonferroni posttests showed significant differ-
ences between treatment groups (P  .05) for the 0.5-, 1-, 2-, and 4-h
time points for all except control ic vs. Cpl-1 ic at 0.5 h and Cpl-1 ic vs.
Cpl-1 ip at 4 h.
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(figure 1, gray circles). The reduction of bacterial titers in CSF is
concomitant to the presence of Cpl-1 in the same compartment.
In contrast to CSF concentrations after ic injection, Cpl-1
showed a prolonged presence for up to 3 h after ip injection of
200 mg/kg, ranging from 7 to 12 g/mL of CSF (figure 2B and
2C).
Discussion. Here, we demonstrated the ability of Cpl-1, a
phage lytic enzyme, to rapidly kill S. pneumoniae in an infant rat
model of bacterial meningitis when injected ic or ip. A single ic
injection of Cpl-1 decreased CSF bacterial counts to below the
detection limit as early as 30 min after injection. This effect was
evident for up to 3 h after administration, after which time bac-
teria in CSF were detected again. The antibacterial effect of Cpl-1
is temporally defined by the 16-min half-life in CSF. Increasing
the bioavailability of Cpl-1 in CSF by multiple ic injections was
attempted, but these repetitive injections proved to be exces-
sively harmful to the animals (data not shown).
Cpl-1 has been investigated previously for in vivo therapeutic
use in 2 murine sepsis models. In one model, mice were infected
and Cpl-1 was injected intravenously [6]. In the other model,
both the infection and Cpl-1 administration were performed by
ip injection [4]. In both models, Cpl-1 was able to rapidly reduce
blood titers. Furthermore, the half-life of Cpl-1 in plasma was
estimated to be20 min [4], a value similar to what we observed
in the CSF of infected animals. In contrast to these previous
sepsis experiments, in which bacterial eradication was achieved
only when Cpl-1 was administered within 4 h after infection, we
initiated therapy only after clinical signs of PM had developed
(i.e., at 18 h after infection) [6]. In the present study, the ob-
served bacterial regrowth in the CSF after 4 h may have been due
to S. pneumoniae transiently invading epithelial or endothelial
cells [14] and thus being out of the reach of Cpl-1. Another
possibility is that a single dose of Cpl-1 is not sufficient to contact
all the pneumococci in the CSF and that additional doses may be
necessary for complete eradication.
Administration of Cpl-1 ip resulted in prolonged systemic re-
lease, as documented by a constant Cpl-1 level in plasma and
CSF for a period of4 h after injection. The amount of Cpl-1 in
the CSF correlated with CSF total protein concentration (data
not shown), suggesting that changes in the blood-brain barrier
may have facilitated the diffusion of Cpl-1 from the blood. Ad-
ministration of Cpl-1 ip (250 mg/kg) led to a Cpl-1 concentra-
tion that was sufficient to decrease CSF bacterial titers by98%
over the first 4 h after administration. We speculate that the
sustained release of biologically active Cpl-1 from the peritoneal
cavity, in conjunction with the breakdown of the blood-brain
barrier during meningitis, explains the extended presence of
Cpl-1 in the CSF.
The data presented in this study identify Cpl-1 as a prom-
ising candidate for antibacterial therapy for several reasons.
The presence of biologically active Cpl-1 in the CSF after ip
application has not been demonstrated to date. This finding
opens new doors for future investigations into the use of
Cpl-1 in the therapy of invasive pneumococcal infections. It
has been shown that Cpl-1 can act synergistically with Pal,
another phage lytic enzyme [15], and (more recently) with
penicillin or gentamicin [9]. Of special interest, Cpl-1 and
penicillin showed synergy against a highly penicillin-resistant
strain in vitro. With respect to emerging resistance, a com-
bined treatment of Cpl-1 with conventional antibiotic ther-
apy could therefore be beneficial. Furthermore, rapid bacte-
rial clearance of the CSF by Cpl-1 in synergy with antibiotics
may prove beneficial, because rapid CSF sterilization has been
associated with an improved outcome of BM [2]. To our
knowledge, the use of phage lysins to control bacterial infec-
tions of the central nervous system has never been demon-
strated.
Figure 2. Assessment of Cpl-1 in cerebrospinal fluid (CSF) and plasma by Western blot. A, Decrease in Cpl-1 concentration in the CSF after
intracisternal (ic) administration of 600 g (black circles). The half-life was determined to be 16 min by fitting a 1-phase exponential decay curve
(dashed line). B, Concentration of Cpl-1 in serum (black diamonds) and CSF (gray diamonds) after intraperitoneal (ip) application of 6 mg. Cpl-1
concentrations remained stable for the time period tested. C, Anti–Cpl-1 Western blots of standards and samples used to perform the densitometric
determination of Cpl-1 concentrations shown in panels A and B.
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Given the emergence of antibiotic-resistant strains, consid-
erable attention is given to alternative antibiotic therapy. In
this context, phage lysins could represent alternatives for
both prophylaxis (e.g., by selective reduction or eradication
of carriage) and treatment by offering rapidity, safety, and
lack of resistance.
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